| Press Releases |
|
June 28, 2010 |
ASTELLAS ANNOUNCES ORAL PRESENTATION OF SGLT2 INHIBITOR DETAILING
SAFETY AND EFFICACY IN PATIENTS WITH TYPE 2 DIABETES AT THE
AMERICAN DIABETES ASSOCIATION MEETING
|
June 9, 2010 |
ASTELLAS COMPLETES ACQUISITION OF OSI PHARMACEUTICALS
|
June 8, 2010 |
ASTELLAS ANNOUNCES SUCCESSFUL COMPLETION OF TENDER OFFER FOR SHARES OF OSI
|
June 3, 2010 |
ASTELLAS ANNOUNCES SUCCESSFUL COMPLETION OF INITIAL TENDER OFFER FOR SHARES OF OSI AND ANNOUNCES SUBSEQUENT OFFER PERIOD
|
May 17, 2010 |
EXPIRATION DATE OF OSI OFFER EXTENDED TO JUNE 2, 2010
|
May 16, 2010 |
ASTELLAS PHARMA INC. TO ACQUIRE OSI PHARMACEUTICALS, INC.
|
May 03, 2010 |
NEW SCIENCE EDUCATION PROGRAM RESPONDS TO PRESIDENT'S
CALL TO HELP YOUNG PEOPLE EXCEL IN SCIENCE
|
April 29, 2010 |
GOVERNOR QUINN ANNOUNCES ASTELLAS PHARMA U.S.
CHOOSES ILLINOIS FOR NEW HEADQUARTERS
|
April 23, 2010 |
EXPIRATION DATE OF OSI OFFER EXTENDED TO MAY 17, 2010
|
April 05, 2010 |
NUMBER OF AMERICANS WILLING TO DONATE ORGANS RISES,
BUT STILL NOT KEEPING PACE WITH NEED
|
March 31, 2010 |
EXPIRATION DATE OF OSI OFFER EXTENDED TO APRIL 23, 2010
|
March 29, 2010 |
ASTELLAS SIGNS CONFIDENTIALITY AGREEMENT WITH OSI
|
March 19, 2010 |
ASTELLAS ANNOUNCES CHANGES TO DIRECTOR NOMINEES FOR ELECTION TO OSI
PHARMACEUTICALS' BOARD OF DIRECTORS
|
March 19, 2010 |
ASTELLAS ANNOUNCES EXPIRATION OF HSR WAITING PERIOD FOR OSI TENDER OFFER
|
March 16, 2010 |
ASTELLAS ANNOUNCES FULL SLATE OF INDEPENDENT DIRECTOR NOMINEES FOR ELECTION AT OSI
PHARMACEUTICALS' 2010 ANNUAL STOCKHOLDERS MEETING
|
March 15, 2010 |
ASTELLAS RESPONDS TO OSI PHARMACEUTICALS' REJECTION
|
March 02, 2010 |
ASTELLAS PHARMA INC. COMMENCES TENDER OFFER TO ACQUIRE ALL OUTSTANDING SHARES OF OSI PHARMACEUTICALS FOR $52 PER SHARE IN CASH
|
March 01, 2010 |
ASTELLAS PHARMA INC. OFFERS TO ACQUIRE OSI PHARMACEUTICALS FOR $52.00 PER SHARE IN CASH
|
January 13, 2010 |
SUMAVELTM DOSEPROTM AVAILABLE IN THE UNITED STATES TO TREAT ACUTE MIGRAINE AND CLUSTER HEADACHES
|
December 07, 2009 |
ASTELLAS INDUCTED INTO NATIONAL MINORITY TRANSPLANT HALL OF FAME MOTTEP HONORS ASTELLAS FOR COMMITMENT TO TRANSPLANT COMMUNITY
|
November 05, 2009 |
THERAVANCE AND ASTELLAS ANNOUNCE THE COMMERCIAL LAUNCH OF
VIBATIVTM (telavancin) IN THE UNITED STATES
|
October 28, 2009 |
CARDIOME AND ASTELLAS ANNOUNCE INITIATION OF PATIENT ENROLMENT IN ACT 5 TRIAL
|
October 26, 2009 |
DONATE LIFE ILLINOIS, ASTELLAS AND THE CHICAGO BEARS PARTNER TO
TACKLE THE SHORTAGE IN HONOR OF BEARS LEGEND, WALTER PAYTON
|
October 22, 2009 |
ZOGENIX AND ASTELLAS ANNOUNCE DATA PUBLISHED SHOWING THE
BENEFITS OF SUMAVELTM DOSEPROTM NEEDLE-FREE DELIVERY SYSTEM
|
October 02, 2009 |
NEW ANALYSIS SUPPORTS TOLERABILITY OF LEXISCAN® (regadenoson) INJECTION FOR PHARMACOLOGIC MYOCARDIAL PERFUSION IMAGING STUDIES
|
|
September 22, 2009
|
ASTELLAS AWARDS EDUCATIONAL SCHOLARSHIPS TO SIX TRANSPLANT RECIPIENTS WHO EMBODY THE SPIRIT OF GIVING BACK
|
|
September 21, 2009
|
ASTELLAS AND THE NATIONAL SCIENCE TEACHERS ASSOCIATION ANNOUNCE 2009 CLASS OF LOCAL SCIENCE EDUCATORS
|
|
September 15, 2009
|
ASTELLAS CELEBRATES THE MIRACLE OF TRANSPLANTATION BY SENDING FIVE RECIPIENTS TO THE 2010 ROSE PARADE®
|
|
September 11, 2009
|
THERAVANCE AND ASTELLAS ANNOUNCE FDA APPROVAL OF VIBATIV™ (telavancin) FOR THE TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
|
|
August 17, 2009
|
CHICAGO MAYOR HONORS ASTELLAS' EXCELLENCE IN LEARNING, DEVELOPMENT
|
|
August 13, 2009
|
UPDATE ON ASTELLAS' REQUEST FOR RIGOROUS TESTING AND SAFETY-RELATED LABELING FOR ANTI-REJECTION MEDICATIONS
|
|
August 10, 2009
|
ASTELLAS SEEKS RIGOROUS TESTING AND SAFETY-RELATED LABELING FOR ANTI-REJECTION MEDICATIONS UNIQUE NEEDS OF TRANSPLANT PATIENTSREQUIRE SPECIAL CARE TO PRESERVE THEIR GIFT OF LIFE
ADDITIONAL CLINICAL TRIAL TO BE CONDUCTED FOR KYNAPID UNDER FDA SPECIAL PROTOCOL AGREEMENT
|
|
August 3, 2009
|
ZOGENIX AND ASTELLAS ENTER EXCLUSIVE CO-PROMOTION AGREEMENT IN THE US
FOR NEWLY APPROVED SUMAVELTM DOSEPROTM
|
|
June 25, 2009
|
ASTELLAS INFORMS CUSTOMERS OF MARKET WITHDRAWAL OF SPECIFIC PRODUCT LOTS
|
|
June 04, 2009
|
ASTELLAS ADDS CNS THERAPY AREA LEADER TO GLOBAL R&D TEAM
|
|
June 01, 2009
|
ASTELLAS HIRES NEW VICE PRESIDENT OF COMPLIANCE
|
|
May 28, 2009
|
ASTELLAS RECEIVES FDA APPROVAL FOR USE OF PROGRAF® (TACROLIMUS) IN CONJUNCTION WITH MYCOPHENOLATE MOFETIL (MMF) IN KIDNEY TRANSPLANT RECIPIENTS
|
|
May 28, 2009
|
ASTELLAS ANNOUNCES NEW VICE PRESIDENT OF MARKETING
|
|
April 1, 2009
|
ASTELLAS APPOINTS NEW US PRESIDENT AND CEO
|
|
March 31, 2009
|
ASTELLAS LAUNCHES VAPRISOL® (CONIVAPTAN HYDROCHLORIDE INJECTION) PREMIXED IN 5% DEXTROSE FOR THE TREATMENT OF HYPONATREMIA
|
|
March 16, 2009
|
ASTELLAS TO TERMINATE OFFER FOR CV THERAPEUTICS
|
|
March 6, 2009
|
ASTELLAS TO NOMINATE TWO DIRECTORS AND SUBMIT PROPOSAL TO REMOVE REMAINING FOUR DIRECTORS OF CV THERAPEUTICS
|
|
February 27, 2009
|
ASTELLAS FILES LAWSUIT AGAINST CV THERAPEUTICS
|
|
February 27, 2009
|
ASTELLAS COMMENCES TENDER OFFER TO ACQUIRE ALL OUTSTANDING SHARES OF CV THERAPEUTICS FOR $16 PER SHARE IN CASH
|
|
February 23, 2009
|
ASTELLAS PHARMA ISSUES STATEMENT REGARDING CV THERAPEUTICS REJECTION OF ALL-CASH PROPOSAL
|
|
January 27, 2009
|
ASTELLAS PROPOSES TO ACQUIRE CV THERAPEUTICS FOR $16 PER SHARE IN CASH
|
|
October 22, 2008
|
FDA APPROVES ASTELLAS' VAPRISOL® CONIVAPTAN HYDROCHLORIDE INJECTION) PREMIXED IN 5% DEXTROSE FOR THE TREATMENT OF HYPONATREMIA |
|
October 14, 2008
|
ASTELLAS RIDE OF A LIFETIME CONTEST SENDS FIVE TRANSPLANT RECIPIENTS TO RIDE FLOAT IN 2009 ROSE PARADE®
|
|
October 01, 2008
|
ASTELLAS JOINS FORCES WITH THE NATIONAL SCIENCE TEACHERS ASSOCATION TO SUPPORT LOCAL SCIENCE EDUCATORS
|
|
August 11, 2008
|
CARDIOME AND ASTELLAS ANNOUNCE RECEIPT OF FDA APPROVABLE LETTER FOR KYNAPIDTM
|
|
June 24, 2008
|
ASTELLAS LAUNCHES LEXISCANTM (REGADENOSON) INJECTION FOR USE AS A PHARMACOLOGIC STRESS AGENT IN RADIONUCLIDE
MYOCARDIAL PERFUSION IMAGING (MPI)
|
|
April 10, 2008
|
CV THERAPEUTICS AND ASTELLAS ANNOUNCE FDA APPROVAL FOR LEXISCANTM (REGADENOSON) INJECTION
|
|
March 25, 2008
|
CIRCULATION PUBLISHES DATA SHOWING KYNAPID (VERNAKALANT HYDROCHLORIDE) INJECTION RAPIDLY CONVERTED SHORT-DURATION ATRIAL FIBRILLATION TO SINUS RHYTHM
|
|
January 22, 2008
|
FDA APPROVES ADDITIONAL INDICATION FOR ASTELLAS MYCAMINE®
|
|
January 21, 2008
|
CARDIOME AND ASTELLAS ANNOUNCE REGULATORY UPDATE
|
|
December 11, 2007
|
FDA ADVISORY COMMITTEE RECOMMENDS APPROVAL OF KYNAPID FOR ACUTE ATRIAL FIBRILLATION
|
|
November 7, 2007
|
STUDY SHOWS VERNAKALANT HYDROCHLORIDE IS EFFECTIVE IN CONVERSION TO NORMAL HEART RHYTHM IN ATRIAL FIBRILLATION PATIENTS FOLLOWING CARDIAC SURGERY
|
|
October 25, 2007
|
STUDY SHOWS VAPRISOL® IS EFFECTIVE IN INCREASING SERUM SODIUM LEVELS AND WELL-TOLERATED IN PATIENTS WITH EUVOLEMIC OR HYPERVOLEMIC HYPONATREMIA
|
|
October 22, 2007
|
ADENOSCAN® PATENT LAWSUITS SETTLED
|
|
October 22, 2007
|
THERAVANCE RECEIVES FDA APPROVABLE LETTER FOR TELAVANCIN FOR THE TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
|
|
October 17, 2007
|
Astellas Pharma US, Inc. AND THE INTERNATIONAL TRANSPLANT NURSES SOCIETY (ITNS) COLLABORATE ON CONTENT FOR
TRANSPLANT EXPERIENCE PROGRAM
|
|
October 11, 2007
|
ASTELLAS RIDE OF A LIFETIME CONTEST SENDS FIVE TRANSPLANT RECIPIENTS TO RIDE FLOAT IN 2008 ROSE PARADE
|
|
March 02, 2007
|
FDA APPROVES ASTELLAS VAPRISOL® FOR THE TREATMENT OF HYPERVOLEMIC HYPONATREMIA
|
|
February 26, 2007
|
Astellas Pharma US, Inc.'s "TRANSPLANT EXPERIENCE" PROGRAM RECEIVES NATIONAL RECOGNITION
|
|
February 19, 2007
|
CARDIOME AND ASTELLAS ANNOUNCE ACCEPTANCE OF NDA FOR REVIEW |
|
October 29, 2006
|
Astellas Pharma US, Inc., GLAXOSMITHKLINE, AND VESIcare® (SOLIFENACIN SUCCINATE) SPONSOR THE #18 RACE CAR AT ATLANTA MOTOR SPEEDWAY TO RAISE AWARENESS ABOUT OVERACTIVE BLADDER |
|
July 25, 2006
|
STUDY DEMONSTRATES IMPROVED RENAL FUNCTION AND LIPID VALUES IN KIDNEY TRANSPLANT PATIENTS ON PROGRAF ® COMPARED TO PATIENTS TAKING NEORAL ® |
|
April 26, 2006
|
ASTELLAS LAUNCHES VAPRISOL® FOR THE TREATMENT OF EUVOLEMIC HYPONATREMIA IN HOSPITALIZED PATIENTS |
|
April 3, 2006
|
ASTELLAS TO ACQUIRE AMEVIVE® (ALEFACEPT) |
|
April 1, 2006
|
ASTELLAS RECEIVES FDA APPROVAL OF PROGRAF® (TACROLIMUS) FOR USE IN HEART TRANSPLANT RECIPIENTS |
|
March 31, 2006
|
NEW DRUG APPLICATION SUBMITTED FOR RSD1235 |
|
January 19, 2006
|
ASTELLAS EDUCATES AND INFORMS PHYSICIANS AND PATIENTS ON CHANGES TO PROTOPIC LABEL IN U.S. |
|
December 30, 2005
|
FDA APPROVES ASTELLAS' VAPRISOL® FOR THE TREATMENT OF EUVOLEMIC HYPONATREMIA |
|
November 7, 2005
|
THERAVANCE AND ASTELLAS TO COLLABORATE ON TELAVANCIN, INVESTIGATIONAL ANTIBIOTIC FOR SERIOUS INFECTIONS |
|
October 19, 2005
|
CARDIOME AND ASTELLAS INITIATE ACT 4 STUDY |
August 10, 2005
|
RAGADENOSON MEETS PRIMARY ENDPOINT IN FIRST PHASE 3 TRIAL |
|
May 24, 2005
|
THREE CLINICAL STUDIES DEMONSTRATE ONCE-DAILY MODIFIED RELEASE PROGRAF® FORMULA TO BE PROMISING TREATMENT OPTION |
|
May 24, 2005
|
NEW STUDIES OF IMMUNOSUPPRESSIVE REGIMENS LIMITING OR AVOIDING THE USE OF STEROIDS SHOW EXCELLENT GRAFT SURVIVAL IN TRANSPLANT RECIPIENTS ON A PROGRAF®-BASED (TACROLIMUS) REGIMEN
|
|
May 13, 2005
|
ANTI-FUNGAL AGENT MYCAMINETM AVAILABLE TO PHYSICIANS
|
|
April 1, 2005
|
YAMANOUCHI, FUJISAWA UNITE TO FORM Astellas Pharma US, Inc., NORTH AMERICAN HEADQUARTERS TO BE IN CHICAGO
|
